1. Home
  2. LNTH vs PCVX Comparison

LNTH vs PCVX Comparison

Compare LNTH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantheus Holdings Inc.

LNTH

Lantheus Holdings Inc.

HOLD

Current Price

$100.62

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$59.16

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNTH
PCVX
Founded
1956
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
7.0B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
LNTH
PCVX
Price
$100.62
$59.16
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$87.00
$88.25
AVG Volume (30 Days)
1.1M
927.4K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.91
N/A
Revenue
$343,374,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$14.19
N/A
P/E Ratio
$34.60
N/A
Revenue Growth
3.62
N/A
52 Week Low
$49.67
$30.81
52 Week High
$111.86
$65.00

Technical Indicators

Market Signals
Indicator
LNTH
PCVX
Relative Strength Index (RSI) 45.87 49.25
Support Level $100.51 $58.51
Resistance Level $101.43 $63.39
Average True Range (ATR) 0.51 2.10
MACD 0.11 -0.37
Stochastic Oscillator 43.84 17.73

Price Performance

Historical Comparison
LNTH
PCVX

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: